Servatus begins dosing in world-first microbiome-focused rheumatoid arthritis trial

Servatus Biopharmaceuticals Ltd director and CEO Wayne Finlayson gives Andrew Scott from Proactive a brief recap on the company which has two platforms, Engineered Protein for treatment of autoimmune disease, and Microbial Biotherapeutics for treatment of inflammatory conditions and bacterial infections. Servatus has announced that it has started dosing in rheumatoid arthritis trial. Finlayson discusses the company’s preclinical animal studies and recruitment for patients to take part in the trial.
#ServatusBiopharmaceuticals #clinicaltrial #asx #proactiveaustralia #proactiveinvestors

You might like

© 2022 The Latest StockMarket News and Interviews